A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4)
Triple-negative breast cancer often has devastating outcomes and treatment options remain limited. Therefore, different treatment combinations are worthy of testing. The efficacy of a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (EpCAM) (9C4) to treat breast c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_9_18 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850248643930488832 |
|---|---|
| author | Naiim S. Ali John M. Akudugu Roger W. Howell |
| author_facet | Naiim S. Ali John M. Akudugu Roger W. Howell |
| author_sort | Naiim S. Ali |
| collection | DOAJ |
| description | Triple-negative breast cancer often has devastating outcomes and treatment options remain limited. Therefore, different treatment combinations are worthy of testing. The efficacy of a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (EpCAM) (9C4) to treat breast cancer was tested. Efficacy was tested with an MDA-MB-231 human breast cancer xenograft model. Anti-EpCAM (9C4) was demonstrated to bind to MDA-MB-231 human adenocarcinoma cells in vitro. Subsequently, mice-bearing MDA-MB-231× enografts were treated with either 131I-anti-EpCAM (9C4), unlabeled anti-EpCAM (9C4), paclitaxel, doxorubicin, or a cocktail of all of the agents. Tumor volume was measured for up to 70-day postinjection. Exponential regression was performed on tumor growth curves for each of the therapy groups. Statistical comparison of the growth constants λ of the regression models for each of the treatment groups with that of the cold antibody and control groups was done using extra sum-of-square F-tests. Biexponential clearance of 131I-anti-EpCAM (9C4) was observed with biological clearance half-times of 1.14 and 17.6 days for the first and second components, respectively. The mean growth rate of the tumors in animals treated with a cocktail of all of the agents was slower than in those treated with unlabeled anti-EpCAM (9C4) (P = 0.022). These preliminary data suggest that a cocktail of 131I-anti-EpCAM (9C4), paclitaxel, and doxorubicin may be suitable for treating breast cancers with high expression of EpCAM. |
| format | Article |
| id | doaj-art-8f1ccdd1bdab41688b5b2e557b094ad5 |
| institution | OA Journals |
| issn | 1450-1147 1607-3312 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | World Journal of Nuclear Medicine |
| spelling | doaj-art-8f1ccdd1bdab41688b5b2e557b094ad52025-08-20T01:58:38ZengThieme Medical and Scientific Publishers Pvt. Ltd.World Journal of Nuclear Medicine1450-11471607-33122019-01-011801182410.4103/wjnm.WJNM_9_18A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4)Naiim S. Ali0John M. Akudugu1Roger W. Howell2Division of Radiation Research, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USADivision of Radiation Research, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USADivision of Radiation Research, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USATriple-negative breast cancer often has devastating outcomes and treatment options remain limited. Therefore, different treatment combinations are worthy of testing. The efficacy of a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (EpCAM) (9C4) to treat breast cancer was tested. Efficacy was tested with an MDA-MB-231 human breast cancer xenograft model. Anti-EpCAM (9C4) was demonstrated to bind to MDA-MB-231 human adenocarcinoma cells in vitro. Subsequently, mice-bearing MDA-MB-231× enografts were treated with either 131I-anti-EpCAM (9C4), unlabeled anti-EpCAM (9C4), paclitaxel, doxorubicin, or a cocktail of all of the agents. Tumor volume was measured for up to 70-day postinjection. Exponential regression was performed on tumor growth curves for each of the therapy groups. Statistical comparison of the growth constants λ of the regression models for each of the treatment groups with that of the cold antibody and control groups was done using extra sum-of-square F-tests. Biexponential clearance of 131I-anti-EpCAM (9C4) was observed with biological clearance half-times of 1.14 and 17.6 days for the first and second components, respectively. The mean growth rate of the tumors in animals treated with a cocktail of all of the agents was slower than in those treated with unlabeled anti-EpCAM (9C4) (P = 0.022). These preliminary data suggest that a cocktail of 131I-anti-EpCAM (9C4), paclitaxel, and doxorubicin may be suitable for treating breast cancers with high expression of EpCAM.http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_9_18chemotherapydoxorubicinepithelial cell adhesion moleculeiodine-131monoclonal antibodypaclitaxelradioimmunotherapy |
| spellingShingle | Naiim S. Ali John M. Akudugu Roger W. Howell A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4) World Journal of Nuclear Medicine chemotherapy doxorubicin epithelial cell adhesion molecule iodine-131 monoclonal antibody paclitaxel radioimmunotherapy |
| title | A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4) |
| title_full | A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4) |
| title_fullStr | A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4) |
| title_full_unstemmed | A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4) |
| title_short | A preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel, doxorubicin, and 131I-anti-epithelial cell adhesion molecule (9C4) |
| title_sort | preliminary study on treatment of human breast cancer xenografts with a cocktail of paclitaxel doxorubicin and 131i anti epithelial cell adhesion molecule 9c4 |
| topic | chemotherapy doxorubicin epithelial cell adhesion molecule iodine-131 monoclonal antibody paclitaxel radioimmunotherapy |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_9_18 |
| work_keys_str_mv | AT naiimsali apreliminarystudyontreatmentofhumanbreastcancerxenograftswithacocktailofpaclitaxeldoxorubicinand131iantiepithelialcelladhesionmolecule9c4 AT johnmakudugu apreliminarystudyontreatmentofhumanbreastcancerxenograftswithacocktailofpaclitaxeldoxorubicinand131iantiepithelialcelladhesionmolecule9c4 AT rogerwhowell apreliminarystudyontreatmentofhumanbreastcancerxenograftswithacocktailofpaclitaxeldoxorubicinand131iantiepithelialcelladhesionmolecule9c4 AT naiimsali preliminarystudyontreatmentofhumanbreastcancerxenograftswithacocktailofpaclitaxeldoxorubicinand131iantiepithelialcelladhesionmolecule9c4 AT johnmakudugu preliminarystudyontreatmentofhumanbreastcancerxenograftswithacocktailofpaclitaxeldoxorubicinand131iantiepithelialcelladhesionmolecule9c4 AT rogerwhowell preliminarystudyontreatmentofhumanbreastcancerxenograftswithacocktailofpaclitaxeldoxorubicinand131iantiepithelialcelladhesionmolecule9c4 |